Evidence map›Paper›PMID 35837606›Full record

SynthesisFrontiers in cardiovascular medicine2022

Cardiorenal Syndrome in COVID-19 Patients: A Systematic Review.

Ling Lin, Yangqin Chen, Dongwan Han, Andrew Yang, Amanda Y Wang, Wenjie Qi

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ling LinDepartment of Infectious Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Yangqin ChenDepartment of Infectious Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Dongwan HanDepartment of Infectious Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Andrew YangDepartment of General and Acute Care Medicine, Royal North Shore Hospital, Sydney, NSW, Australia.
Amanda Y WangConcord Clinical School, The University of Sydney, Sydney, NSW, Australia.
Wenjie QiDepartment of Infectious Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNConcord Repatriation General Hospital · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To perform a systematic review assessing the clinical manifestations and outcomes of cardiorenal syndrome or the presence of both cardiac and renal complications in the 2019 coronavirus disease (COVID-19) patients. Methods: All relevant studies about cardiorenal syndrome or both cardiac and renal complications in COVID-19 patients were retrieved on PUBMED, MEDLINE, and EMBASE from December 1, 2019 to February 20, 2022. Results: Our search identified 15 studies including 637 patients with a diagnosis of cardiorenal syndrome or evidence of both cardiac and renal complications followingSARS-CoV-2 infection. They were male predominant (66.2%, 422/637), with a mean age of 58 years old. Cardiac complications included myocardial injury (13 studies), heart failure (7 studies), arrhythmias (5 studies), or myocarditis and cardiomyopathy (2 studies). Renal complications manifested as acute kidney injury with or without oliguria. Patients with cardiorenal injury were often associated with significantly elevated levels of inflammatory markers (CRP, PCT, IL-6). Patients with a diagnosis of cardiorenal syndrome or evidence of both cardiac and renal complications had more severe disease and poorer prognosis (9 studies). Conclusion: The presence of either cardiorenal syndrome or concurrent cardiac and renal complications had a significant impact on the severity of the disease and the mortality rate among patients with COVID-19 infection. Therefore, careful assessment and management of potential cardiac and renal complications in patients with COVID-19 infection are important to improve their outcomes.

Indexed as

cardiac complicationscardiorenal syndrome (CRS)COVID-19renal complicationsSARS-CoV-2

Identifiers

PMID35837606
PMCPMC9273837
OpenAlexW4283642479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.